KospicyKorean filings in English
Filings / METABIOMED.CO.,LTD

Material Event Report — Share Buyback Decision

METABIOMED.CO.,LTD · 주요사항보고서(자기주식취득결정)

8-KKOSDAQ · 059210 Filed 2026-11-17Korean original on DART

English form view 61% translated

Translated from a fixed dictionaryLeft in Korean (free text, names)Numbers and dates are copied unchanged

Material Event Report (Treasury Stock Acquisition Decision)

6.3

(주)메타바이오메드

Material Event Report / KRX Mandatory Disclosure

To: Financial Services Commission / Korea Exchange2026-11-17
Company Name:주식회사 메타바이오메드
CEO:오 석 송
Head Office Address:충북 청주시 흥덕구 오송읍 오송생명1로 270
(Tel) 043-218-1981
(홈페이지) http://www.meta-biomed.com
Preparer:(직 책) 상무이사(성 명) 윤 종 필
(Tel) 043-218-1981

Decision on treasury stock acquisition

1. Shares to Be Acquired (shares)Common Shares277,777
Other Shares-
2. Planned Acquisition Amount (KRW)Common Shares1,000,000,000
Other Shares-
3. Expected Acquisition PeriodStart Date2026-11-18
End Date2026-12-31
4. Expected Holding PeriodStart Date-
End Date-
5. Purpose of Acquisition1. 자기주식 취득 및 소각을 통한 주주가치 제고2. 직원 성과보상 활용을 통한 동기부여 강화
6. Acquisition Method코스닥시장을 통한 장내 직접취득
7. Entrusted Investment BrokerNH Investment & Securities
8. Treasury Shares Held Before AcquisitionAcquisition within distributable profits (shares)Common Shares770,000Ratio (%)2.83
Other Shares-Ratio (%)-
Other Acquisitions (shares)Common Shares-Ratio (%)-
Other Shares-Ratio (%)-
9. Acquisition Resolution Date2026-11-17
- Independent (Outside) Directors* PresentPresent (persons)-
Absent (persons)1
- Auditor (audit committee member not an independent (outside) director*) attendanceAbsent
10. Daily Purchase Order Limit (1 days)Common Shares27,777
Other Shares-

* Independent directors for listed companies; outside directors for unlisted companies

11. Other Matters Relevant to Investment Decisions
(주1) 취득예정금액: 1,000,000,000원- 취득예정금액은 이사회결의일 전일의 종가(3,600원) 기준이며 실제 취득금액은 향후 주가변동에 따라 달라질 수 있습니다.(주2) 취득예상기간은 주주가치 제고를 위해 최대한 기말 전까지 완료할 예정이며, 취득 경과에 따라 조기종료 될 수 있습니다.(주3) 보유예상기간은 본 건으로 취득 예정인 자기주식은 취득 완료 후 일정 기간 내 소각 및 직원 성과보상 재원 활용 예정이므로 기재를 생략하였습니다. 단 상기 수량은 본 보고서 제출일 현재 예상되는 수량으로 실제 자기주식 취득결과와 상이할 수 있으며 실제 소각 및 직원 성과보상 재원으로 활용되는 수량 또한 변동될 수 있습니다.(주4) 1일 매수 주문수량 한도 : 27,777주※ 산출근거 : [①과 ② 중 많은 수량]과 ③ 중 적은 수량 ① 취득신고 주식수의 10% : 27,777주 ② 이사회결의전 1개월간 일평균거래량의 25% : 25,742주 ③ 발행주식총수의 1% : 271,714주
【Treasury Share Acquisition Limit】
ItemAmount
1. Distributable Profit Limit under the Commercial Act as of Prior Fiscal Year-Enda. Net Assets125,659,846,271
b. Share Capital14,047,150,500
C. Sum of Capital Reserve and Legal Reserve Accumulated through Prior Fiscal Year54,799,649,748
D. Unrealized Gains Prescribed by Presidential Decree-
Subtotal (A-B-C-D)56,813,046,023
2. Treasury Share Acquisition Amount Since Prior Fiscal Year-End2,992,124,059
3. Dividends Resolved at the AGM Since Prior Fiscal Year-End and Related Legal Reserve3,125,783,199
4. Quarterly/Interim Dividends Resolved by the Board Since Prior Fiscal Year-End and Related Legal Reserve-
5. Trust Contract Amount-
6. Acquisition Cost of Treasury Shares Disposed Since Prior Fiscal Year-End (Moving Average Method)2,982,320,546
Treasury share acquisition limit (1-2-3-4-5+6)53,677,459,311
【Treasury Shares Held Before Acquisition Resolution】
(Unit: shares)
Acquisition methodType of SharesBeginning quantityChange in quantityEnding quantityRemarks
Acquired (+)Disposed (-)Retired (-)
Acquisition within distributable profitsDirect acquisitionDirect On-Market AcquisitionCommon Shares1,031,243770,000108,387922,856770,000-
Other Shares------
Direct OTC acquisitionCommon Shares------
Other Shares------
Tender offerCommon Shares------
Other Shares------
Subtotal (a)Common Shares1,031,243770,000108,387922,856770,000-
Other Shares------
Acquisition under trust agreementShares held by trusteeCommon Shares------
Other Shares------
Shares held in kindCommon Shares------
Other Shares------
Subtotal (b)Common Shares------
Other Shares------
Other acquisitions (c)Common Shares------
Other Shares------
Total (a+b+c)Common Shares1,031,243770,000108,387922,856770,000-
Other Shares------